All Access

Health Tech Deals

Standard

Health Tech Deals Thought Bubble

Thought Bubble

Health Tech Deals Alerts

Alert

mustard

BFD Expert Voices - Health Tech Deals

BFD Expert Voices

Ardan Equity is investing in Clinical Ink alongside existing backer GI Partners, valuing the pharma tech company at $400 million, Axios Pro has learned. 

Ardan and GI Partners each will own roughly half the company, three sources say.

Catch up quick: Clinical Ink was marketed on more than $100 million in revenue and about $30 million of EBITDA.

Centerview and Guggenheim ran a process that drew interest from sponsors like TPG and General Atlantic, Axios Pro reported in June.

Clinical Ink's software lets trial sponsors and CROs collect and analyze clinical data from patients and sites. GI Partners acquired it in 2020.

Zoom out: Sponsor-backed clinical trial tech continues to consolidate.

LLR-backed Suvoda combined with Thoma Bravo-owned Greenphire last year in a $1.9 billion transaction, with Bain also investing in the combined company.

Ardan and GI Partners declined to comment. 

Scoop: Ardan Equity investing in Clinical Ink at $400M valuation

It's investing alongside existing backer GI Partners.

Illustration of a grid consisting of colorful rectangles, the back of a one hundred dollar bill, and photographs of a prescription pill bottle, a microscope, and a hand holding a molecular genetics testing tray.

<p>Ardan Equity is investing in Clinical Ink alongside existing backer GI Partners, valuing the <a class="gtmContentClick" data-vars-link-text="pharma tech" data-vars-click-url="https://www.axios.com/pro/health-tech-deals/2026/03/09/health-care-exit-backlog" data-vars-content-id="2208b550-b67b-4e08-b5aa-1f5f38245999" data-vars-headline="Scoop: Ardan Equity investing in Clinical Ink at $400M valuation" data-vars-event-category="story" data-vars-sub-category="story" data-vars-item="in_content_link" href="https://www.axios.com/pro/health-tech-deals/2026/03/09/health-care-exit-backlog" target="_self">pharma tech</a> company at $400 million, Axios Pro has learned. </p><ul><li>Ardan and GI Partners each will own roughly half the company, three sources say.</li></ul>

topics

politics-policy

epstein-files

donald-trump

2026-midterm-elections

immigration

behind-the-curtain

race-and-equity

technology

privacy-tech-regulation

automation-and-ai

tiktok-news

big-tech

social-media

cybersecurity

economy

social-security

inflation

tariffs

federal-reserve

transportation

business

c-suite

retail-news

media

elon-musk

dealmaking

health

rfk-jr

drug-prices

axios-explains-abortion

public-health

world

israel

axios-explains-ukraine

iran

russia

china

energy-climate

nuclear-energy

climate-energy-policy

climate-change

extreme-weather

alternative-energy

electric-vehicles

science

emerging-tech

biomedicine

newsletters

charlotte

salt-lake-city

denver

fort-lauderdale

cincinnati

scottsdale

boulder

kansas-city

austin

chicago

dallas

detroit

atlanta

indianapolis

nashville

nw-arkansas

columbus

hollywood

washington-dc

north-of-cincy

mesa

richmond

san-francisco

boston

des-moines

houston

phoenix

miami

philadelphia

seattle

new-orleans

colorado-springs

huntsville

raleigh

san-antonio

twin-cities

pittsburgh

san-diego

tampa-bay

portland

cleveland

arapahoe

douglas

axios-local

axios-pro

axios-live

the-axios-show

Scoop: Ardan Equity investing in Clinical Ink at $400M valuation

What to read next